Office Action 2: Notice of Allowance (2025-02-28)

CLAIMS:
In the Claims:

1\. (Original) A polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence set forth in SEQ ID NO: 11, wherein the polypeptide comprises an alanine or glutamine substitution at position 47 and an alanine or glutamine substitution at position 354.

2\. (Original) The polypeptide of claim 1, wherein the polypeptide comprises an amino acid sequence at least 96% identical to the amino acid sequence set forth in SEQ ID NO: 11, wherein the polypeptide comprises an alanine or glutamine substitution at position 47 and an alanine or glutamine substitution at position 354.

3\. (Original) The polypeptide of claim 1, wherein the polypeptide comprises an amino acid sequence at least 97% identical to the amino acid sequence set forth in SEQ ID NO: 11, wherein the polypeptide comprises an alanine or glutamine substitution at position 47 and an alanine or glutamine substitution at position 354.

4\. (Original) The polypeptide of claim 1, wherein the polypeptide comprises an amino acid sequence at least 98% identical to the amino acid sequence set forth in SEQ ID NO: 11, wherein the polypeptide comprises an alanine or glutamine substitution at position 47 and an alanine or glutamine substitution at position 354.

5\. (Original) The polypeptide of claim 1, wherein the polypeptide comprises an amino acid sequence at least 99% identical to the amino acid sequence set forth in SEQ ID NO: 11, wherein the polypeptide comprises an alanine or glutamine substitution at position 47 and an alanine or glutamine substitution at position 354.

6\. (Original) The polypeptide of claim 1, wherein the polypeptide comprises:(a) an alanine substitution at position 47 and position 354;
(b) an alanine substitution at position 47 and a glutamine substitution at position 354;
(c) a glutamine substitution at position 47 and position 354; or (d) a glutamine substitution at position 47 and an alanine substitution at position 354.

7\. (Original) The polypeptide of claim 1, wherein the polypeptide comprises the amino acid sequence set forth in any one of SEQ ID NOs: 283, 286, 295, and 298.

8\. (Original) A nucleic acid molecule encoding the polypeptide of claim 1.

9\. (Original) A nucleic acid molecule encoding the polypeptide of claim 2.

10\. (Original) A nucleic acid molecule encoding the polypeptide of claim 3.

11\. (Original) A nucleic acid molecule encoding the polypeptide of claim 4.

12\. (Original) A nucleic acid molecule encoding the polypeptide of claim 5.

13\. (Original) A nucleic acid molecule encoding the polypeptide of claim 6.

14\. (Original) A nucleic acid molecule encoding the polypeptide of claim 7.

15\. (Original) A recombinant virus expressing the polypeptide of claim 1.

16\. (Original) A recombinant virus expressing the polypeptide of claim 2.

17\. (Original) A recombinant virus expressing the polypeptide of claim 3.

18\. (Original) A recombinant virus expressing the polypeptide of claim 4.

19\. (Original) A recombinant virus expressing the polypeptide of claim 5.

20\. (Original) A recombinant virus expressing the polypeptide of claim 6.

21\. (Original) A recombinant virus expressing the polypeptide of claim 7.

22\. (Original) A composition comprising the polypeptide of claim 1.

23\. (Original) A composition comprising the polypeptide of claim 2.

24\. (Original) A composition comprising the polypeptide of claim 3.

25\. (Original) A composition comprising the polypeptide of claim 4.

26\. (Original) A composition comprising the polypeptide of claim 5.

27\. (Original) A composition comprising the polypeptide of claim 6.

28\. (Original) A composition comprising the polypeptide of claim 7.

OFFICE ACTION:
Notice of Pre-AIA  or AIA  Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
EXAMINER'S AMENDMENT
An examiner’s amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.
Authorization for this examiner’s amendment was given in an interview with Pei Wu on 2/20/25.
The application has been amended as follows:
Page 1, paragraph 0002 line 4 was amended as follows:
1445888 bytes in size.
Conclusion

APPLICANT REBUTTAL: REMARKS
I.
Status of
the Application
Claims 1-28 are pending in the application.
Favorable reconsideration of the subject application is respectfully requested in view of the following remarks. II.
Non-Statutory Obviousness-Type Double Patenting
Claims 1-21 stand rejected on the ground of nonstatutory obviousness-type double patenting as allegedly being unpatentable over claims 1, 11, and 12 of U.S. Patent No. 12,091,434.
Claims 22-28 stand rejected on the ground of nonstatutory obviousness-type double patenting as allegedly being unpatentable over claims 1 and 4 of U.S. Patent No. 12,091,434.
Applicant respectfully disagrees. However, solely to advance prosecution, Applicant is filing a terminal disclaimer herewith. III.
Conclusion